Pharmac Proposes Funding for Prasugrel to Enhance Cardiovascular Treatment Options
Pharmac is currently inviting public feedback on a new proposal aimed at funding prasugrel, a medication designed to lower the risk of blood clots and serious cardiovascular events. This initiative targets individuals who have experienced a heart attack or have undergone treatments such as angioplasty or stent insertion.
Enhancing Treatment Choices for Patients
Michaela Lion, the Manager of Pharmaceutical Funding at Pharmac, emphasized the importance of this proposal, stating that the inclusion of prasugrel would offer a critical treatment alternative for patients in need of anticoagulant therapy.
“Post-heart attack or post-procedure, patients are often prescribed anticoagulants to prevent blood clot formation and minimize the risk of future cardiovascular incidents,” explained Lion.
Diverse Patient Needs
According to Lion, not every medication is effective for each patient, and some individuals may not respond well to currently funded treatments due to allergies, intolerance, or diminished efficacy.
“By funding prasugrel, we can provide clinicians with an important option to better accommodate individual patient needs,” she added.
A Return to Availability
Prasugrel was previously available in New Zealand but became unavailable after its supplier discontinued it in 2021. “Reviving this medication will expand the treatment options for approximately 4,000 patients at risk of serious cardiovascular complications,” Lion noted.
Convenience in Treatment Administration
Prasugrel is administered once daily, which may enhance compliance for some patients.
Public Consultation Open Until November 25
The consultation period for feedback remains open until 25 November. Stakeholders and the general public are encouraged to share their insights through the online consultation form or by emailing consult@pharmac.govt.nz.
Advertisement – scroll to continue reading
© Scoop Media
Discussion about this post